Marine n-3 fatty acids (FAs) may exert beneficial effects on inflammation, fibrosis, and endothelial function, which could preserve renal graft function. In this randomized controlled trial, 132 Norwegian renal transplant recipients received either 2.6 g of marine n-3 FAs or olive oil (control) daily for 44 weeks, in addition to standard care. Thirty patients did not complete the trial. The primary endpoint was change (Δ) in measured glomerular filtration rate (mGFR) during follow-up. We found no significant difference in Δ mGFR between the marine n-3 FA group and controls (6.7 vs 3.8 mL/min per 1.73 m 2 , P = .15). Significant beneficial effects from marine n-3 FA supplementation were, however, seen in secondary endpoints plasma triglycerides, plasma high-sensitivity C-reactive protein, and brachial artery flow-mediated dilation. In the per-protocol population, the renal graft indices percent interstitial fibrosis and Chronic Allograft Damage Index also were significantly lower in the marine n-3 FA group. The cumulative incidence of adverse events did not differ between the marine n-3 FA group (n = 218) and controls (n = 240). In conclusion, marine FA supplementation did not improve renal function compared with controls, but was safe, lowered plasma triglyceride and high-sensitivity C-reactive protein levels, and improved endothelial function (Clinical.Trials.gov identifier NCT01744067).
| INTRODUC TI ON
During recent decades, improved surgical procedures and tailored immunosuppressive regimens have lowered the risk of graft loss during the first few years after renal transplantation, while long-term graft survival has remained virtually unchanged.
1 Silent alloimmune-mediated tissue injury and immunosuppressive drug side-effects are major contributors to progressive renal graft fibrosis, the key histological correlate for chronic allograft nephropathy and a predictor of graft survival. 2, 3 Agents that may improve endothelial function or possess anti-inflammatory or antifibrotic properties would be attractive, since they might increase longevity of grafts. Experimental and clinical trials in various patient populations report anti-inflammatory effects by the major marine n-3 fatty acids (FAs) eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), through synthesis of less pro-inflammatory compounds compared with those derived from arachidonic acid, inhibition of nuclear factor kappa B, and synthesis of inflammation-resolving mediators resolvins and protectins. [4] [5] [6] [7] Marine n-3
FAs improve FA oxidative phosphorylation, reduce triglyceride levels, and possibly improve endothelial function. [8] [9] [10] [11] Marine n-3
FAs have also been linked to prevention of alloimmune-mediated tissue injury and premature aging in renal grafts, production of regulatory T cells, and inhibition of the pro-fibrotic transforming growth factor β-1/Smad signaling pathway. 5, [12] [13] [14] [15] A recent randomized clinical trial (RCT) in myocardial infarction survivors reported less development of myocardial fibrosis in patients who received high-dose marine n-3 FA supplements. 16 We have previously shown that higher plasma phospholipid marine n-3 FA levels were associated with better patient and graft survival in a large cohort (n = 1990) of Norwegian renal transplant recipients. 17, 18 In that observational cohort, plasma marine n-3 FA levels were inversely associated with plasma creatinine, inflammatory biomarkers and triglycerides, acute rejections beyond the early posttransplant phase, and development of interstitial fibrosis (IF) during the first year after transplantation. [17] [18] [19] [20] [21] The present study is the largest RCT investigating the effects of marine n-3 FA supplementation in renal transplantation performed to date, and the first to include data on renal graft histopathological indices and endothelial function. The main objective of this trial was to evaluate whether daily supplementation of 2.6 g marine n-3 FAs for 44 weeks, compared with controls, would improve renal function beyond standard care in renal transplant recipients.
| MATERIAL S AND ME THODS

| Study participants
Inclusion criteria of the present trials were age ≥18 years, a functional graft (estimated glomerular filtration rate according to the Chronic Kidney Disease Epidemiology Collaboration formula >30 mL/min per 1.73 m 2 at 6-8 weeks posttransplant) and written informed consent. 22 Exclusion criteria were allergy to fish, other seafoods or the study drug, a kidney donor >75 years old, participation in another Patients were randomly allocated to receive either marine n-3
FAs (n = 66) or control oil (n = 66) by computer-generated randomization codes (SAS, Cary, NC) provided by the Monitor. Allocation concealment was ensured by the randomization method, where study participants, caregivers, and investigators were kept blinded until the final monitoring visit at May 25, 2017 , and by using hard capsules of similar shape and color in both study groups. At the final visit the electronic case report form and the study data file were locked and randomization codes were made available. There were no code breaks before unblinding.
| Study visits, endpoints, and procedures
Study duration was 44 weeks. Study measurements were performed at baseline (8 weeks posttransplant) and at the end of study (1 year after transplantation). Data were entered into an electronic case report form at the baseline visit, at scheduled telephone interviews during follow-up, and 4 weeks after the final visit, at additional visits in case of serious adverse events, and at the final visit. 
| Sample size
Power estimation was based on an absolute difference in Δ mGFR of 8.0 mL/min per 1.73 m 2 between the study groups and a 20% dropout rate. To ensure adequate statistical power, we calculated that 132 patients had to be included in the trial.
| Statistical analysis
Primary and secondary endpoints were analyzed in intention-to-treat (ITT) and per-protocol (PP) populations. Kolmogorov-Smirnov test and normality plots were used to assess normality. Difference in Δ values for study endpoints between the marine n-3 FA and control group was evaluated by Student t test for normally distributed data and MannWhitney U test for nonnormally distributed data. A similar statistical approach was used for evaluation of baseline and end-of-study endpoint values. We used Fisher exact test to evaluate differences in the cumulative incidence of adverse events between the study groups.
A 2-sided P value of <.05 was considered statistically significant. We 
| RE SULTS
| Demographics
Patient characteristics are presented in Table 1 . In general, the groups were well matched, but there was a higher prevalence of hypertension in the marine n-3 FA group. Median baseline plasma marine n-3 FA level was 6.0 wt% in both study groups (interquartile range 4.7-7.3 wt%). In patients who received marine n-3 FA supplements and completed the trial, we found a mean absolute increase in plasma marine n-3 FA levels of 4.0 wt%, while it remained unchanged in the control group (Table 2) .
| Renal function
Renal function improved during follow-up in both study groups ( (Table S1 ). There was no significant difference in Δ mGFR between the marine n-3 FA group and controls (6.7 ± 11.7 vs 3.8 ± 10.3 mL/min per 1.73 m 2 , P = .15, Figure S1 ).
| Renal graft fibrosis and chronic allograft damage
In patients who completed the trial, the degree of IF in the renal cortex remained stable in the marine n-3 FA group (12.9% ± 11.5% at baseline and 12.5% ± 10.3% at the end of study) while it increas ed in controls (from 12.6% ± 10.2% at baseline to 16.0% ± 13.0% at the end of study). The difference between the study groups for Δ percent IF was statistically significant in PP analysis (−0.6% ± 9.0% in the marine n-3 FA group compared with 3.6% ± 11.1% in controls, P = .04), but not in ITT analysis (Table 2 and Figure S1 ). Similarly, in PP analysis, the CADI score remained stable during follow-up in the marine n-3 FA group, while it increased in controls (Table S1) , and Δ CADI differed significantly between the groups (Table 2) .
| Proteinuria and inflammation
FEPR was reduced during follow-up in both of the groups and there was no significant difference in Δ FEPR between the study groups ( Table 2 ).
The degree of graft inflammation was slightly higher at the end of study than at baseline for both study groups (Table S1 ). There was no significant difference in Δ percent graft inflammation between the groups (Table 2 and Figure S1 ). Marine n-3 FA supplementation reduced hsCRP from 4.6 ± 10.2 mg/L at baseline to 3.5 ± 4.0 mg/L at the end of study, as opposed to an increase in the control group from 3.2 ± 4.3 mg/L at baseline to 5.9 ± 8.1 mg/L at the final visit (Table S1 ). Thus Δ hsCRP differed significantly between the study groups ( Table 2 ).
| Endothelial function
Mean baseline postocclusion brachial artery diameter was 0.2 mm (≈5%) larger than the corresponding resting value. During follow-up the difference between postocclusion and resting values increased by 0.1 mm (≈2%) on average in the marine n-3 FA group, while it remained stable in controls. We found a corresponding significant increase in Δ percent flow-mediated dilation in the marine n-3 FA group compared with controls (2.0% ± 3.8% vs 0.5% ± 2.4%, P = .02, Figure S1 ).
| Blood lipids and glucose
Plasma triglyceride levels decreased significantly in the marine n-3
FA group during follow-up as opposed to controls (−39.8 ± 74.2 vs −7.8 ± 77.2 mg/dL, P = .02). Marine n-3 FA supplementation had no effect on plasma HDL, LDL, or total cholesterol levels, fasting plasma glucose, or 2-hour postchallenge plasma glucose (Table 3) .
| Blood pressure and arterial stiffness
There was a slight reduction in systolic blood pressure and pulse wave velocity during follow-up in both study groups, while diastolic blood pressure remained unchanged (Table S2 ). Marine n-3 FA supplementation had no effect on pulse wave velocity or blood pressure (Table 3) .
| Safety and study drug adherence
A detailed description of adverse events, reasons for withdrawal from the trial, and study drug adherence are given in the supplemental material. In short, 30 patients (of whom 16 belonged to the marine n-3 FA group) did not complete the trial. Two patients were termed screening failure by the Monitor and 2 patients did not meet at the final visit (Figure 1 ). During follow-up, there were 218 adverse events in the marine n-3 FA group compared with 240 adverse events in the control group (Table 4) . Gastrointestinal discomfort was the most frequent complaint in both the marine n-3 FA group (26%) and the control group (32%), especially early after study drug initiation, and led to patient withdrawal in 17 cases (9 in the marine n-3 FA group and 8 in controls). One patient in the marine n-3 FA group died due to cancer. Graft failure occurred in 1 patient in the control group. There were 15 acute rejections in 11 patients in the marine n-3 FA group and 16 acute rejections in 14 patients in the control group. Baseline patient characteristics and plasma phospholipid levels of major n-3 and n-6 polyunsaturated FA are presented as percentage for categorical data, median (interquartile range), or mean value (standard deviation) for continuous variables. Differences between groups were evaluated with χ 2 for dichotomous categorical data, Mantel-Haenszel linear trend for other categorical variables, Mann-Whitney U test for dialysis vintage, FEPR, and renal graft indices and Student t test for other continuous variables. ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CADI, Chronic Allograft Damage Index; eGFR, estimated glomerular filtration rate (CKD-EPI formula); FA, fatty acid; FEPR, fractional excretion of protein in urine; HLA, human leukocyte antigen; hsCRP, plasma high-sensitivity C-reactive protein; mGFR, measured glomerular filtration rate; wt%, weight percentage of total plasma phospholipid fatty acids.
TA B L E 1 (Continued)
There was no significant difference in tacrolimus trough levels at end of study between the groups (marine n-3 FA group:
6.19 ± 2.04 µg/L vs controls: 5.86 ± 1.66 µg/L, P = .33). Also tacrolimus doses were similar between the study groups (mean dose 4.8 ± 2.4 mg in the marine n-3 FA group vs 4.6 ± 2.6 mg in controls, P = .45).
Adherence to study treatment was evaluated by plasma marine n-3 FA levels. In addition, we performed a pill count at the final visit.
In the PP population, 5 patients who received marine n-3 FA supplements missed ≥5% of doses.
| Plasma marine n-3 fatty acid levels and study endpoints
Subgroup and post-hoc analyses were performed in the ITT popula- Figure S2 ) or other study endpoints, including renal graft inflammation (r = −0.11, P = .31, Figure S2 ).
Subgroup analysis showed that patients with lower than median baseline plasma marine n-3 FA level (<6.0 wt%, n = 61) had a significant increase in Δ mGFR after marine n-3 FA supplementation compared with controls (8.2 ± 12.6 vs 1.6 ± 11.2 mL/min per 1.73 m 2 , P = .04). Change in plasma marine n-3 FA level during follow-up was higher in patients with lower baseline levels (r = −0.35, P = .01, Figure S3 ).
Patients with acute or chronic acute rejections at the final visit (n = 5) had higher percent graft inflammation, but the low number of cases made comparison between the study groups unreliable.
Excluding these patients from the analysis did not influence results. TA B L E 2 Effects of marine n-3 FA supplementation on change in renal endpoints during follow-up
| D ISCUSS I ON
The main finding in this study was that no significant improvement in renal function could be demonstrated after 44 weeks of marine n-3
FA supplementation compared with controls. However, some beneficial findings were seen in secondary endpoints. Plasma triglyceride and hsCRP levels were significantly reduced and flow-mediated dilation improved during follow-up in the marine n-3 FA group compared with controls. In the PP population, percent IF and CADI remained stable in the marine n-3 FA group, as opposed to an increase in these histopathological indices in controls during follow-up.
Previous RCTs investigating the effects of marine n-3 FA supplementation in renal transplant recipients were hampered by low sample sizes and short study duration. 28, 29 Although renal function improved after marine n-3 FA supplementation in some studies, most trials reported a nonsignificant increase in Δ mGFR of 3-5 mL/ Differences between the marine n-3 FA group and the control group (olive oil) were evaluated by Student t test. BP, blood pressure; FA, fatty acid; HDL, high-density lipoprotein; ITT, intention-to-treat population; LDL, low-density lipoprotein; PP, per-protocol population; 2hPG, 2-h postchallenge plasma glucose during an oral glucose tolerance test; SD, standard deviation.
TA B L E 4 Adverse events
Variables
Marine n-3 FA Controls P
Number of patients 66 66
Number of adverse events 218 240 .33
Acute rejection episode 15 16
Chronic antibody-mediated rejection 1 1
De novo donor-specific antibodies 3 3
Polyoma virus nephropathy 1 0
Polyoma virus viremia 5 3
Cytomegalovirus disease 2 4
Cytomegalovirus viremia 4 9
Recurrence of primary renal disease 2 3
Posttransplantation diabetes mellitus
7
Transplant ureter stenosis 1 3
Coronary artery disease 0 2
Peripheral artery stenosis 0 2 Cancer (solid organ) 2 2
Cancer (skin) 1 1
Septicemia 4 4
Lower respiratory tract infection
6
Urinary tract infection 5 15
Gastrointestinal discomfort (abdominal pain, diarrhea, nausea, or regurgitation)
21
Adverse events during 44 weeks of follow-up. Difference between the marine n-3 FA group and the control group was evaluated by Fisher exact test. In addition, the distribution of selected adverse events is given. FA, fatty acid.
min per 1.73 m 2 . 29 Meta-analyses of these RCTs (n = 733-812 patients included) found no statistically significant effect on renal function. 28, 29 The mean increase in Δ plasma marine n-3 FA level of 4.0 wt% in the marine n-3 FA group approximates the difference between the lower and upper plasma marine n-3 FA quartile in a large observational study of Norwegian renal transplant recipients. In that study, beneficial associations between plasma marine n-3 FA level and renal function was only shown beyond 3 years posttransplant,
suggesting that potential renoprotective effects of marine n-3 FAs might prevent decline in renal function in the long run.
Most studies in renal transplant recipients report a significant reduction in plasma triglycerides after marine n-3 FA supplementation, but no significant effect on plasma total or LDL cholesterol levels, blood pressure, or proteinuria, 28, 29 in line with findings in the present study. The triglyceride-lowering effect of marine n-3 FAs has been repeatedly shown in various patient populations. 9 A small increase in HDL cholesterol level was reported in a meta-analysis of RCTs, 29 but was not shown in the present study.
We found a reduction in plasma hsCRP levels in the marine n-3
FA group compared with controls, suggesting an effect on low-grade systemic inflammation. However, we found no significant effect of marine n-3 FA supplementation on percent renal graft inflammation.
Hernandez and colleagues investigated the effects of marine n-3 FA supplementation (effective dose of 1.9 g EPA plus DHA/d) on renal graft inflammation during the first 3 months after transplantation. 30 In that trial, markers of tumor necrosis factor pathway activation in renal graft tissue, obtained by fine-needle aspiration, were lower during acute rejection episodes in patients who received marine n-3
FA supplements compared with controls. However, they found no difference in inflammatory biomarkers between the study groups in patients without rejection.
Chronic inflammation is linked to endothelial dysfunction. 31 We found an improvement in percent flow-mediated dilation in patients who received marine n-3 FA supplements, consistent with reports in patients with dyslipidemia and metabolic syndrome. Chronic inflammation is also linked to development of fibrosis in native and transplanted kidneys. 2 In the present study, we found RCTs investigating the effects of marine n-3 FA supplementation are scarce in patients with chronic kidney disease. 34 Donadio and colleagues performed a study in an American IgA nephropathy cohort and found less decline in renal function after supplementation of 3.2 g of EPA plus DHA per day for 2 years compared with controls. 35 However, later trials have not reproduced this finding, and there is currently not sufficient evidence to recommend marine n-3 FA supplementation in glomerulonephritis or chronic kidney disease. 34 Patients in the present trial had high baseline plasma marine n-3 FA levels, typical of patients on a Nordic diet rich in fish and seafood and about 5 times higher than levels reported from American cohorts. 17, 36, 37 Patients with low baseline levels (<6.0 wt%) had a steeper increase in plasma marine n-3 FA level after supplementation and a statistically significant improvement of mGFR during follow-up compared with controls. These findings suggest that patients with low background marine n-3 FA consumption might be more likely to benefit more from marine n-3 FA supplementation. Most other RCTs focusing on marine n-3 FAs in renal transplant recipients have been performed in the Mediterranean countries or in The Netherlands, where consumption of fish and seafoods is also relatively high. 28, 29 Thus, similar studies performed in regions with a low consumption of marine n-3 FAs are warranted. Also, explorative studies investigating effects of marine n-3 FA consumption on mechanisms involved in development of renal graft fibrosis would be of interest. 7, 12, 38, 39 The cumulative incidence of adverse events during follow-up did not differ between the groups. Gastrointestinal discomfort was experienced by nearly a third of the patients and is common in renal transplant recipients receiving mycophenolate and tacrolimus. 40 Discontinuation of the study drug resolved the problem in about half of these patients. Previous RCTs focusing on marine n-3 FA supplementation in renal transplant recipients report very limited data on adverse events. 28, 29 Marine n-3 FA supplementation did not significantly influence tacrolimus trough concentrations. However, dedicated pharmacokinetic studies are needed to evaluate marine n-3 FAs interaction with immunosuppressive drugs. 23 Based on RCTs performed to date, including the present study, there is not sufficient evidence to recommend the use of marine n-3 FA supplements in renal transplantation. However, the safety of marine n-3 FAs is well documented and clinical trials report beneficial effects on renal and cardiovascular risk factors that may converge into improved patient and graft survival, as suggested from observational data. 17, 18 Thus, larger studies with longer duration are needed to investigate whether marine n-3 FAs preserve renal function and improve patient and graft survival.
Strengths of this study include a well-described cohort, FA analysis performed at baseline and end of study, criterion standard measurement of renal function, flow-mediated dilation and pulse wave velocity measurements, renal histopathological indices, measurement of several other cardiovascular risk factors, and monitoring of adverse events and concomitant medication during follow-up.
However, this study also has some important limitations. The study duration might have been too short for postulated effects on endothelial function and graft fibrosis to translate into improved renal function. The subgroup analyses were hampered by low sample sizes, increasing the risk of type II errors. Thirty patients did not complete the trial (23% dropout rate). Most adverse events and patient withdrawals occurred during the first 2 months of follow-up. In retrospect, inclusion of patients at 4-6 months posttransplant might have been more appropriate. We used olive oil as the control oil in this study, which may not be inert. 41 Finally, study participants were mainly white men, limiting generalizability.
In conclusion, this study demonstrated that supplementation 
